ST. PAUL, Minn., Oct. 4, 2013 /PRNewswire/ -- Prime Therapeutics' (Prime) efforts to improve patient health and reduce health care costs were recognized on Oct. 1 at the URAC Quality Summit in Washington, D.C. Prime's Controlled Substance Drug Utilization Review (DUR) program and its positive results with Florida Blue were honored with the prestigious Silver Award in the Care Coordination and Clinical Integration category.
"Prime Therapeutics is committed to innovation that improves the safety and lowering overall cost of care for its members," said Eric Elliott, president and CEO at Prime Therapeutics. "This recognition confirms that our efforts are an industry best practice and encourages us to continue to leverage our unique connections to deliver programs that help people get the medicine they need to feel better and live well."
The Controlled Substance DUR program is a component of Prime's GuidedHealth(®)( )platform and specifically helps health plans and health care professionals identify potential misuse and abuse of controlled substance medications. The program has been implemented by most of Prime's clients.
The Controlled Substance DUR program was presented by Prime experts at the URAC Quality Summit prior to the awards program.
About Prime Therapeutics
Prime Therapeutics LLC (Prime) helps people get the medicine they need to feel better and live well. Prime manages pharmacy benefits for health plans, employers, and government programs including Medicare and Medicaid. The company processes claims and delivers medicine to members, offering clinical services for people with complex medical conditions. Headquartered in St. Paul, Minn., Prime serves nearly 23 million people. It is collectively owned by 13 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. Prime has been recognized as one of the fastest-growing private companies in the nation.
For more information, visit www.primetherapeutics.com or follow @Prime_PBM on Twitter.
SOURCE Prime Therapeutics LLC